Vanrafia (atrasentan) wins MFDS approval in South Korea for IgA nephropathy, making Korea the first country outside the US to ...

By Deena Beasley Nov 2 (Reuters) - The recent failure of a Novartis experimental heart drug in a large trial raised questions ...

The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.

BioArctic AB (BIOA B) announced that collaborator Novartis has decided to terminate an option, collaboration and license agreement signed in August 2025 that was aimed at exploring a potential ...

Investor Relations Executive Director - Isabella Singh ...

Novartis (SWX:NOVN) reported new trial data showing Votrient plus Roche's Avastin improved overall survival in certain ...

Novartis AG improved its full-year profit outlook on Tuesday after stronger demand for newer medicines helped offset generic ...

Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, citing an internal portfolio decision unrelated to the platform.

BioArctic AB (BRCTF) announced that Novartis (NVS) has notified BioArctic that it has decided to terminate the Option, ...

SALES FORECAST: The Swiss drugmaker is expected to report quarterly sales of $14.9 billion, according to consensus estimates provided by Visible Alpha. For the same quarter last year, the company ...

Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...

A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have ...